BIO China Advisory Committee
 |
George Baeder George Baeder is a Partner of Monitor Group Asia. George has focused on the region's emerging markets. He has worked across a broad spectrum of industries—including fast moving consumer products, pharmaceuticals, specialty chemicals, oil and gas, natural resources, telecommunications, data processing, consumer electronics and financial services. George also leads Monitor's life sciences practice in the Asia/Pacific region, covering ethical pharmaceuticals, OTC, medical devices and healthcare delivery. After studying economics and Chinese history in the U.S. and Taiwan, George joined Business International Corp, a New York based business advisory firm in 1973. In 1976 he moved to Hong Kong to build the company's Asian operations. After selling Business International in 1986, George founded the Pacific Rim Consulting Group, a strategy boutique, which he sold to AT Kearney in 1997. Before joining Monitor, George was a Senior Advisor to Asian Capital Partners. |
 |
Xue Baizhong Xue Baizhong is the founder of Nuokang Biopharma and has been chairman and chief executive officer since inception in November 1997. Mr. Xue has extensive experience in research and development, sales and marketing and corporate management. Mr. Xue is currently the vice chairman of the China Biochemical Industrial Association and the executive vice chairman of Liaoning Biotechnology Association. Mr. Xue holds a bachelor's degree in biochemistry from Jilin University, China and a master's degree in microbiology from the Microorganism Research Institute of Shandong University, China. |
 |
Helen Chen Helen Chen is a director and partner of L.E.K. Consulting based in Shanghai. She is the co-head of the China office and a member of L.E.K.’s Global Leadership Team, the firm’s governing committee. Helen has over 20 years of consulting and industry experience in the U.S. and Asia, and has resided in China since 2000. Helen is the head of L.E.K.’s China life sciences practice, with extensive case work and industry experience covering the full bio/pharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness. She is on the Editorial Board of PharmAsia and on the Advisory CommitteeforBIO China. Helen is a sought after speaker and author on the opportunities and issues in the China healthcare and life sciences. Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China. She was an associate director of finance at Genentech and a sales planner at Abbott Laboratories. She was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997, and was honored by Who’s Who Among American Women from 1993 to 1995. Helen received her AB cum laude in applied mathematics from Harvard University. |
 |
Leon Chen Dr. Chen is Founder and Managing Partner of Frontline BioVentures. He has over eighteen years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1,000 Talent Project, and an adviser to BioBAY of Suzhou Industry Park. As a venture capital investor, Dr. Chen's current and past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board). As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). As a PhD scientist, he worked with Schering Plough (New Jersey), and is a key member of the discovery team of Zytia / Vytorin - a multi-billion drug. Dr. Chen was a Post-Doc at MIT, PhD (with top honor) from the University of Louvain, Louvain-La-Neuve, BS from Peking University. He holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report. |
 |
Li Chen Dr. Li Chen is the co-founder and CEO of Hua Medicine, a Chinese biotech company focused on the discovery and development of novel medicines for unmet medical needs in China and the rest of the world. He was previously the Chief Scientific Officer at the Roche R&D Center China, as well as a member of Roche’s Pharma Research Leadership Team. As a founding Director in this position, Dr. Chen was responsible for the development and implementation of Roche China drug discovery strategy, the creation of a China discovery portfolio, and the management of China operations. He also developed a “Collaborative Innovation” model through integration of over 100 scientist-based China partnerships with academic institutes, biotech, contract research organizations and clinical research organizations. During his 18 year pharma career, Dr. Chen also had several leadership positions at Roche Nutley in New Jersey, including Head of high throughput chemistry and project leadership in metabolic diseases and cancer. He is a co-inventor of two Roche drugs that have completed Phase II clinical trials in Asthma and in MED. He also served as a member at Roche’s Patent Coordination Committee at Nutley. Dr. Chen was the President of the Sino-American Pharmaceutical Professionals Association (SAPA) in 2001, and is now a member of the SAPA Board of Directors. |
 |
Bill Guo, PhD Dr. Bill Guo is the Chairman and founder of Venturepharm Group, a leading full-service and pharmaceutical company in Asia. He led the company’s flagship Venturpharm Lab to become the first CRO listed in Hong Kong. He has over 9 years of global pharmaceutical experience working as a researcher to a senior executive with companies such as Johnson & Johnson, Novapharm and Venturpharm Canada. He also has 8 years of entrepreneurial experience in China. Dr. Guo received his PhD in pharmaceutics as well as an MSc in industrial pharmacy from the University of Toronto. He has also attended the MBA program at Herriot Watt University and received executive education from Judge Business School, University of Cambridge UK. Fortune magazine has recognized him as one of China’s entrepreneurs to watch. He also received the 2005 National Labor Hero award from the State Council of China, has been named one of the ten best management elites in China, was the sole winner of the 2003Youth Chinese Entrepreneur Award organized by Asia Business Week, and has received many other accolades throughout his career. |
 |
May-Kin Ho, PhD Dr. Ho is an advisory director to the firm. Previously, she was a biotechnology analyst and co-head of US Healthcare for Global Investment Research. She joined Goldman Sachs in 1992 and was named managing director in 1998 and partner in 2002. Dr. Ho has been ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for over 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times. Prior to joining the firm, she held senior management positions in research, marketing and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company. Dr. Ho serves on the board of The Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University and the Investment Committee of the Society for Neuroscience. She has also served on the Biological Chemistry Advisory Council at Harvard Medical School. Dr. Ho was a postdoctoral fellow at Harvard Medical School. She earned a PhD in Microbiology and Immunology from the State University of New York, Downstate Medical Center. |
 |
James Li Dr. James Li is the Vice President and General Manager, Amgen China where he is leading the company’s efforts in expanding business into the Chinese market and helping Chinese patients to access Amgen’s vital medicines. Prior to joining Amgen, Dr,. Li was a Partner at Kleiner Perkins Caufield & Byers’ life sciences practice, first in the US Pandemic Fund and later, in its China Fund. He successfully invested in a number of early stage and growth stage companies, and led a portfolio company that went to public in 2010. From 1991 to 2006, Dr. Li spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across the Asia Pacific Region when the Vaccine Division started operations in the region; he also successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s largest franchise in Asia. Dr. Li received his Medical Degree from Shanghai Medical University, followed by a Master of Science degree in Microbiology from the University of Montana. |
 |
Aihua Pan, PhD, MD Dr. Aihua Pan is the Chairman of the Board of Directors, SinoBioway Group Co., Ltd., Sinobiocorp Group Co., Ltd., SinoVAC Biotech Co., Ltd., Guangzhou Bioway Biotech Co., Ltd., Xiamen Bioway Biotech Co., Ltd., Bioway Bioway TCM Co., Ltd., Beijing Bioway KaiTuo Agricultural Biotech Co., Ltd., Beijing Bioway BOSI Biointelligence Technology Co., Ltd., Beijing Bioway Fortune Research Centre for Gene Drugs Co., Ltd., and the Director of Beijing Times Research Centre for Bio-Economy. He is also an Executive Director of Chinese Biomedical Engineering Society and the Vice-Chairman of Industry Promotion Committee, Chinese Biomedical Engineering Society, as well as Deputy Director of China Medicinal Biotech Association (CMBA). He is also a member of program implementation feasibility study committee of National Key Special Project “Treatment and Prevention for HIV/AIDS and Viral Hepatitis Pandemics”. Dr. Pan has been actively involved in biopharmaceutical research and development as well as management for 30 years. Dr. Pan is the Principal Investigator of several MOST-funded State 863 Key Projects covering subjects such as: Protein Engineering of Metallothionein and Large-scale Production Technology for Nucleic Acid and Peptide Drugs. Dr. Pan is one of the core experts and participates in national strategic policy making and planning on “China Biological Industry Development” and “China's Biopharmaceutical Industry”, organized by National Development and Reform Commission (NDRC) and Ministry of Science and Technology (MOST). Dr. Pan graduated in Medicine from Hunan Medical University in 1984 and holds PhD degrees in Biochemistry and Political Economy from Peking University. Currently, Dr. Pan is the Professor of Biomedical Engineering at School of Life Sciences, Peking University. He has made outstanding contributions to academia and industry, and was named one of the 10 Most Pioneering Entrepreneurs of the 21st Century by New Financial Economics (2001), and one of the 10 Most Valuable Professional Managers by TALENTS Magazine (2001). |
 |
Rajesh Parekh Rajesh (Raj) is the leader of McKinsey’s Asia Pharmaceuticals and Medical Products Practice. He joined McKinsey’s Chicago office in 1996 and since 2005 has worked in our Shanghai office. He serves clients across the pharmaceutical and medical device and equipment sectors on their Asian businesses, with a focus on China, India, and Japan. Raj’s work spans a range of areas including growth strategy, sales & marketing and R&D. Raj led McKinsey’s internal knowledge effort to assess the impact of the recent healthcare reform on the medical device and equipment industry in China. Recent medical device and equipment experience includes working with a global implantable medical device leader to develop breakthrough growth strategies for China and India; helping a leading hospital infusion equipment player assess attractiveness of the “value segment” in China and develop product and customer segmentation approach to capture the most attractive opportunities; and working with a leading medical device company to develop organization blueprint to manage the emerging market set of countries. Raj holds a PhD in Chemical Engineering from University of Illinois at Urbana-Champaign and a BS in Chemical Engineering from University of California at San Diego. |
|
Yinxiang Wang, Ph.D. |
|
 |
Jerry Xiao Dr. Xiao received his Ph.D. in Pharmacology from The Second Military Medical University. While in his postdoctoral training at the University of Rochester, he founded a small pharmaceutical company in the U.S. Before joining FosunPharma in June 2008, he was an investment manager at a VC company. Currently, he is responsible for identifying, evaluating, and developing new product and technology opportunities from the whole globe, as well as directing FosunPharma Group’s investments to R&D companies. He has invested in two R&D companies and in-licensed three projects for FosunPharma. He is also a member of the Board of Directors of Fochon Pharma and Henlius Biotech |
 |
Steve Yang Dr. Steve Yang is Vice President, Head of R&D for Asia and Emerging Markets at AstraZeneca. He is based in Shanghai, China and is responsible for developing, implementing and aligning the company’s R&D strategy for Asia and Emerging Markets. Prior to joining AstraZeneca, Dr. Yang was Vice President, Head of Asia R&D at Pfizer, where he was charged with establishing and expanding the company’s research partnership network with academic institutions, biotechnology firms and Contract Research Organizations across Asia Pacific. He was also responsible for delivering a portfolio of preclinical and clinical stage projects targeting unmet medical needs of emerging markets. Prior to his leadership position in Asia, Dr. Yang was Executive Director and head of the company’s global R&D strategic management group. Before joining Pfizer Dr. Yang held a number of positions at IntraBiotics Pharmaceuticals, a US-based biotech company and also worked for Strategic Decisions Group (SDG), a management consulting firm for Fortune 100 companies. Dr. Yang is the co-founder of the BayHelix Group, a non-profit professional organization of Chinese life science business leaders. Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, USA. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude in Biology from Michigan Technological University, USA. |
 |
Tony Zhang Tony Zhang received his BS degree in chemistry from Shandong University. With the help of a CGP Fellowship, he obtained his PhD from Purdue University in 1989 under the direction of Professor Ei-ichi Negishi，a 2010 Noble Laureate. After a short stint as a research scientist at Reilly Inc (now Vertellus), he joined Eli Lilly in 1992, and led multi-disciplined teams engaged in drug development. He is recognized as a premier molecule builder, and has patented, published, and lectured extensively in synthetic chemistry, pharmaceutical process development and R&D efficiencies. Tony has been a key initiator and implementer of the company’s R&D network in China since 1999, and has served as the founding site head for Eli Lilly Global R&D, China, with responsibilities including development of R&D strategies, establishment and management of research collaborations, and licensing activities for molecular assets and research technologies in Asia. Tony has served as the board chairman (2010-11) for the BayHelix Group. He is an advisory board member for a number of governmental and nonprofit organizations, universities, and the journal Org Process R&D. |
|
Xu Zhang |
